AUTHORS
Jordan K Schaefer, MD, MSc, Felix Valbuena, MD2, Samantha B Schon, MD3, Sarah Bailey, PhD4, Charley Jiang, MS5, Esperanza Igram, MPH6, Gina Aliste, AAS7, Kirsten Trzeciak, BS8, Ingrid Ramirez, BS9, Susie Williamson, MA10, Ganesa Wegienka, PhD11, David Williams, PhD12, Jennifer Garner, PhD, RD13, Erica E Marsh, MD, MSCI, FACOG14
AFFILIATIONS
1 University of Michigan, Ann Arbor, Michigan, United States
2 Community Health and Social Services Center, Detroit, Michigan, United States
3 University of Michigan, Ann Arbor, Michigan, United States
4 Bridges Into the Future, Flint, Michigan, United States
5 University of Michigan, Ann Arbor, Michigan, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 University of Michigan, Ann Arbor, Michigan, United States
8 University of Michigan, Ann Arbor, Michigan, United States
9 University of Michigan, Ann Arbor, Michigan, United States
10 Corewell Health West, Flint, Michigan, United States
11 Henry Ford Health, Detroit, Michigan, United States
12 Harvard University, Boston, Massachusetts, United States
13 University of Michigan, Ann Arbor, Michigan, United States
14 University of Michigan, Ann Arbor, Michigan, United States
ABSTRACT
Introduction: Millions of individuals in the United States are affected by potentially treatable iron deficiency anemia. Anemia is associated with increased morbidity and mortality, and its disease burden is influenced by social determinants of health. Very few studies have leveraged community engagement to better understand anemia prevalence and epidemiology.
Methods: The “Menstruation and Anemia Research: A Community Health Study (MARCH)” study makes use of community based participatory research (CBPR) methods. A Steering Committee of 16 leaders from local, community-based organizations joined with academic partners to direct the overall study, with an initial goal to better understand the burden of anemia in the community. This effort is part of a larger strategy to improve anemia recognition, diagnosis, and management. Specifically, the study seeks to develop a scalable multicomponent community-based intervention to improve anemia evaluation and management.
From May 2025 to April 2026, the MARCH study team offered point of care (POC) anemia screening using the HemoCue Hb 801 system among adults able to provide informed consent, and able to understand/speak in English or Spanish. Participants were recruited from community events. Participant demographics were collected and area deprivation index values were determined based on patient reported home address. Anemia was defined using institutional reference ranges. Patients with abnormal hemoglobin values were encouraged to see their healthcare provider for further evaluation. Data were analyzed with descriptive statistics and multivariable regression to identify predictors of anemia.
Results: A total of 1,061 people participated (84.6% female sex, 45.5% Black or African American, 30.3% as Hispanic/Latino, and 17.4% White).
Of the total sample, 364 (34.3%) patients were anemic, with an average (standard deviation) hemoglobin of 10.8 (1.2) versus 12.6 (1.7) g/dL in those without anemia; 5 participants had a hemoglobin ≤7 g/dL with the lowest hemoglobin being 4.2 g/dL. Anemia prevalence differed by age, gender, area deprivation index, menstruation status, and race in univariable analysis.
Multivariable regression analyses indicated higher odds of anemia among Black relative to White participants (OR = 3.43, 95% CI [2.24-5.25]) and women relative to men (OR = 2.67, 95% CI [1.72-4.15]). Compared to individuals aged 21-30, anemia odds were heightened among the youngest and eldest age groups (OR ages 18-20 = 2.67, 95% CI [1.23-5.79]; OR age 70+ = 2.25, 95% CI [1.23-4.13]).
Conclusions: Community based participatory methods were effective to engage diverse populations in a POC anemia screening study, suggesting this could be an effective strategy to improve representation in clinical research. Anemia screening identified clinically significant hemoglobin values among community dwelling individuals that were unaware of their hemoglobin values and not actively seeking medical care; this includes several individuals with hemoglobin values below 7 g/dL, a value that would raise considerations for transfusion. These data add to the ongoing debate regarding the value of anemia screening among asymptomatic adults, something that may become easier over time with advances in screening technologies. There remains a need for further study on the risks and benefits of anemia screening in various contexts.
Finally, the variation in anemia by sociodemographic factors highlights the need for interventions to address disparities. While the racial variation in anemia could be partially explained by hemoglobinopathies such as alpha thalassemia, data have suggested that other factors like socioeconomic status and medical comorbidities are also probable contributors.
Overall, given the high prevalence of anemia, there is an opportunity to address health concerns around this pervasive condition using community engaged approaches, including community health worker driven education and POC testing in the community.
DISCLOSURES
Jordan K Schaefer, MD, MSc: Pfizer - Research Funding; Pharmacosmos - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)